RS57723B1 - Jak1 inhibitori za lečenje mijelodisplastičnog sindroma - Google Patents
Jak1 inhibitori za lečenje mijelodisplastičnog sindromaInfo
- Publication number
- RS57723B1 RS57723B1 RS20181194A RSP20181194A RS57723B1 RS 57723 B1 RS57723 B1 RS 57723B1 RS 20181194 A RS20181194 A RS 20181194A RS P20181194 A RSP20181194 A RS P20181194A RS 57723 B1 RS57723 B1 RS 57723B1
- Authority
- RS
- Serbia
- Prior art keywords
- pyrimidin
- jak1
- pyrrolo
- pharmaceutically acceptable
- pyrazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946124P | 2014-02-28 | 2014-02-28 | |
| PCT/US2015/017963 WO2015131031A1 (en) | 2014-02-28 | 2015-02-27 | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| EP15710994.3A EP3110409B1 (en) | 2014-02-28 | 2015-02-27 | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS57723B1 true RS57723B1 (sr) | 2018-12-31 |
Family
ID=52693052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20181194A RS57723B1 (sr) | 2014-02-28 | 2015-02-27 | Jak1 inhibitori za lečenje mijelodisplastičnog sindroma |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US20150246046A1 (enExample) |
| EP (1) | EP3110409B1 (enExample) |
| JP (1) | JP6576941B2 (enExample) |
| KR (1) | KR20160136323A (enExample) |
| CN (2) | CN106456773A (enExample) |
| AU (1) | AU2015222913B2 (enExample) |
| CA (1) | CA2940659C (enExample) |
| CL (1) | CL2016002144A1 (enExample) |
| CR (1) | CR20160449A (enExample) |
| CY (1) | CY1120857T1 (enExample) |
| DK (1) | DK3110409T3 (enExample) |
| EA (1) | EA201691745A1 (enExample) |
| ES (1) | ES2688553T3 (enExample) |
| HR (1) | HRP20181661T1 (enExample) |
| HU (1) | HUE041456T2 (enExample) |
| IL (1) | IL247475B (enExample) |
| LT (1) | LT3110409T (enExample) |
| MX (1) | MX372939B (enExample) |
| MY (1) | MY185392A (enExample) |
| PE (1) | PE20161388A1 (enExample) |
| PL (1) | PL3110409T3 (enExample) |
| PT (1) | PT3110409T (enExample) |
| RS (1) | RS57723B1 (enExample) |
| SG (2) | SG10201807952PA (enExample) |
| SI (1) | SI3110409T1 (enExample) |
| SM (1) | SMT201800551T1 (enExample) |
| UA (1) | UA121857C2 (enExample) |
| WO (1) | WO2015131031A1 (enExample) |
| ZA (1) | ZA201606610B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3184526T3 (en) | 2005-12-13 | 2019-01-14 | Incyte Holdings Corp | PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| WO2010135621A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| SMT201800137T1 (it) | 2010-03-10 | 2018-07-17 | Incyte Holdings Corp | Derivati di piperidin-4-il azetidina come inibitori di jak1 |
| PH12012502296B1 (en) | 2010-05-21 | 2017-10-06 | Incyte Holdings Corp | Topical formulation for a jak inhibitor |
| SG190839A1 (en) | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| US9181271B2 (en) | 2012-11-01 | 2015-11-10 | Incyte Holdings Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
| PE20151157A1 (es) | 2012-11-15 | 2015-08-19 | Incyte Corp | Formas de dosificacion de ruxolitinib de liberacion sostenida |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| HUE050215T2 (hu) | 2013-01-15 | 2020-11-30 | Incyte Holdings Corp | Pim kináz inhibitorokként hasznos tiazolkarboxamid és piridinkarboxamid vegyületek |
| LT3489239T (lt) | 2013-03-06 | 2022-03-10 | Incyte Holdings Corporation | Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai |
| HRP20231048T1 (hr) | 2013-05-17 | 2023-12-22 | Incyte Holdings Corporation | Derivati bipirazola kao jak inhibitori |
| UA120499C2 (uk) | 2013-08-07 | 2019-12-26 | Інсайт Корпорейшн | Лікування захворювань із застосуванням лікарських форм з уповільненим вивільненням для інгібітора jak1 |
| TW201605866A (zh) | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物 |
| MA39984B1 (fr) | 2014-04-08 | 2020-12-31 | Incyte Corp | Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné |
| MA39987A (fr) | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| WO2017155325A1 (ko) * | 2016-03-09 | 2017-09-14 | 울산대학교 산학협력단 | Jak1 억제제를 유효성분으로 포함하는 줄기세포의 증식, 분화 촉진 또는 노화 억제용 조성물 |
| KR101934107B1 (ko) * | 2016-12-15 | 2018-12-31 | 가톨릭대학교산학협력단 | 골수형성이상 증후군 환자의 저메틸화 제제 치료 반응성 및 생존 예후 예측용 조성물 |
| EP3572415B1 (en) | 2017-01-23 | 2024-03-06 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Jak kinase inhibitor and preparation method and use thereof |
| CN109867676B (zh) * | 2017-12-01 | 2020-10-30 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| IL276302B2 (en) | 2018-01-30 | 2023-11-01 | Incyte Corp | Procedures for preparing [1-(3-fluoro-2-(trifluoromethyl(isonicotinyl}piperidine-4-one) |
| EP3746149B1 (en) | 2018-02-01 | 2025-08-06 | Shifamed Holdings, LLC | Intravascular blood pumps |
| CN118490690A (zh) * | 2018-02-16 | 2024-08-16 | 因赛特公司 | 用于治疗细胞因子相关的病症的jak1通路抑制剂 |
| US11584961B2 (en) | 2018-03-30 | 2023-02-21 | Incyte Corporation | Biomarkers for inflammatory skin disease |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| AU2019252259A1 (en) | 2018-04-13 | 2020-12-03 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| CN112469418A (zh) | 2018-06-01 | 2021-03-09 | 因赛特公司 | 治疗pi3k相关病症的给药方案 |
| CN113490484B (zh) | 2018-10-31 | 2024-08-23 | 因赛特公司 | 治疗血液疾病的组合疗法 |
| CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
| KR20210137087A (ko) * | 2019-03-05 | 2021-11-17 | 인사이트 코포레이션 | 만성 폐 동종이식 기능장애의 치료를 위한 jak1 경로 억제제 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| US12203942B2 (en) | 2019-10-10 | 2025-01-21 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US12360120B2 (en) | 2019-10-10 | 2025-07-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| CN111358791A (zh) * | 2020-03-13 | 2020-07-03 | 深圳百奥捷生物科技有限公司 | Jak/stat信号通路磷酸盐抑制剂在制备治疗dba疾病的药物中的应用 |
| PE20231102A1 (es) | 2020-06-02 | 2023-07-19 | Incyte Corp | Procesos para preparar un inhibidor de jak1 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| US11957661B2 (en) | 2020-12-08 | 2024-04-16 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of vitiligo |
| WO2022152902A1 (en) * | 2021-01-18 | 2022-07-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| IL308216A (en) | 2021-05-03 | 2024-01-01 | Incyte Corp | Jak1 pathway inhibitors for the treatment of prurigo nodularis |
| TW202509019A (zh) * | 2023-04-27 | 2025-03-01 | 香港商維泰瑞隆（香港）生物科技有限公司 | Sarm1調節子、其製劑及用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| CN1152031C (zh) | 1998-08-11 | 2004-06-02 | 诺瓦提斯公司 | 具有血管生成抑制活性的异喹啉衍生物 |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| PL202623B1 (pl) | 2000-06-28 | 2009-07-31 | Smithkline Beecham Plc | Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna |
| AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
| TWI302836B (en) | 2001-10-30 | 2008-11-11 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| JP2008520612A (ja) | 2004-11-24 | 2008-06-19 | ノバルティス アクチエンゲゼルシャフト | ＪＡＫ阻害剤およびＢｃｒ−Ａｂｌ、Ｆｌｔ−３、ＦＡＫまたはＲＡＦキナーゼ阻害剤のうち少なくとも１個の組合せ |
| WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| DK3184526T3 (en) * | 2005-12-13 | 2019-01-14 | Incyte Holdings Corp | PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR |
| ES2602577T3 (es) | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Derivados de azetidina y ciclobutano como inhibidores de JAK |
| ES2487542T3 (es) | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
| WO2011028685A1 (en) | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| SMT201800137T1 (it) | 2010-03-10 | 2018-07-17 | Incyte Holdings Corp | Derivati di piperidin-4-il azetidina come inibitori di jak1 |
| ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| SG190839A1 (en) | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| SG10201509919UA (en) * | 2010-12-03 | 2016-01-28 | Ym Biosciences Australia Pty | Treatment of jak2-mediated conditions |
| WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| WO2013173720A1 (en) * | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| US10155987B2 (en) * | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| US9181271B2 (en) * | 2012-11-01 | 2015-11-10 | Incyte Holdings Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
| HRP20231048T1 (hr) * | 2013-05-17 | 2023-12-22 | Incyte Holdings Corporation | Derivati bipirazola kao jak inhibitori |
-
2015
- 2015-02-27 CR CR20160449A patent/CR20160449A/es unknown
- 2015-02-27 SG SG10201807952PA patent/SG10201807952PA/en unknown
- 2015-02-27 EA EA201691745A patent/EA201691745A1/ru unknown
- 2015-02-27 SM SM20180551T patent/SMT201800551T1/it unknown
- 2015-02-27 CN CN201580017178.XA patent/CN106456773A/zh active Pending
- 2015-02-27 MY MYPI2016001574A patent/MY185392A/en unknown
- 2015-02-27 SG SG11201607083VA patent/SG11201607083VA/en unknown
- 2015-02-27 HU HUE15710994A patent/HUE041456T2/hu unknown
- 2015-02-27 MX MX2016011103A patent/MX372939B/es active IP Right Grant
- 2015-02-27 AU AU2015222913A patent/AU2015222913B2/en active Active
- 2015-02-27 UA UAA201609815A patent/UA121857C2/uk unknown
- 2015-02-27 ES ES15710994.3T patent/ES2688553T3/es active Active
- 2015-02-27 EP EP15710994.3A patent/EP3110409B1/en active Active
- 2015-02-27 HR HRP20181661TT patent/HRP20181661T1/hr unknown
- 2015-02-27 KR KR1020167026668A patent/KR20160136323A/ko not_active Ceased
- 2015-02-27 RS RS20181194A patent/RS57723B1/sr unknown
- 2015-02-27 US US14/633,605 patent/US20150246046A1/en not_active Abandoned
- 2015-02-27 LT LTEP15710994.3T patent/LT3110409T/lt unknown
- 2015-02-27 CN CN202010986614.7A patent/CN112494652A/zh active Pending
- 2015-02-27 SI SI201530368T patent/SI3110409T1/sl unknown
- 2015-02-27 JP JP2016554471A patent/JP6576941B2/ja active Active
- 2015-02-27 PT PT15710994T patent/PT3110409T/pt unknown
- 2015-02-27 CA CA2940659A patent/CA2940659C/en active Active
- 2015-02-27 WO PCT/US2015/017963 patent/WO2015131031A1/en not_active Ceased
- 2015-02-27 PE PE2016001538A patent/PE20161388A1/es unknown
- 2015-02-27 DK DK15710994.3T patent/DK3110409T3/en active
- 2015-02-27 PL PL15710994T patent/PL3110409T3/pl unknown
-
2016
- 2016-08-24 CL CL2016002144A patent/CL2016002144A1/es unknown
- 2016-08-25 IL IL247475A patent/IL247475B/en active IP Right Grant
- 2016-09-23 ZA ZA2016/06610A patent/ZA201606610B/en unknown
-
2018
- 2018-05-15 US US15/980,052 patent/US20190111058A1/en not_active Abandoned
- 2018-11-13 CY CY181101196T patent/CY1120857T1/el unknown
-
2020
- 2020-04-03 US US16/839,972 patent/US20210069193A1/en not_active Abandoned
-
2021
- 2021-12-20 US US17/556,374 patent/US20220378791A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3110409B1 (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
| US9498467B2 (en) | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 | |
| US9193733B2 (en) | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors | |
| US9434725B2 (en) | 5-azaindazole compounds and methods of use | |
| CA2921568A1 (en) | Survival benefit in patients with solid tumors with elevated c-reactive protein levels | |
| RS65624B1 (sr) | Lečenje supurativnog hidradenitisa upotrebom jak inhbitora | |
| MX2010014005A (es) | Compuestos de triazolopiridina inhibidores de jak y los metodos. | |
| RS60824B1 (sr) | Tetrahidro-pirido[3,4-b]indoli kao modulatori estrogenih receptora i njihova upotreba | |
| EP3596064B1 (en) | Tosylacetate based compounds and derivatives thereof as phgdh inhibitors | |
| JP7247092B2 (ja) | キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途 | |
| JP2016517859A (ja) | 癌を治療するための、ｎｉｋ阻害剤としての３−（２−アミノピリミジン−４−イル）−５−（３−ヒドロキシプロピニル）−１ｈ−ピロロ［２，３−ｃ］ピリジン誘導体 | |
| US10654867B2 (en) | Heteroaryl estrogen receptor modulators and uses thereof | |
| WO2021043208A1 (en) | 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | |
| JP2023503322A (ja) | Ｄｕｘ４発現に関連する疾患を処置するための新規化合物 | |
| HK1231762A1 (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
| HK1231762B (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
| BR112016019511B1 (pt) | Uso de inibidores de jak1 para o tratamento de síndromes mielodisplásicas | |
| EA040337B1 (ru) | Ингибиторы jak1 для лечения миелодиспластических синдромов | |
| NZ724464B2 (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
| HK40039222A (en) | Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors | |
| HK40039222B (en) | Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |